TW226374B - - Google Patents

Info

Publication number
TW226374B
TW226374B TW082101189A TW82101189A TW226374B TW 226374 B TW226374 B TW 226374B TW 082101189 A TW082101189 A TW 082101189A TW 82101189 A TW82101189 A TW 82101189A TW 226374 B TW226374 B TW 226374B
Authority
TW
Taiwan
Application number
TW082101189A
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW226374B publication Critical patent/TW226374B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082101189A 1992-02-24 1993-02-19 TW226374B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24

Publications (1)

Publication Number Publication Date
TW226374B true TW226374B (zh) 1994-07-11

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082101189A TW226374B (zh) 1992-02-24 1993-02-19

Country Status (14)

Country Link
EP (1) EP0628043A1 (zh)
JP (1) JPH07504192A (zh)
KR (1) KR100287933B1 (zh)
AU (1) AU675060B2 (zh)
CA (1) CA2130563C (zh)
FI (1) FI105917B (zh)
HU (1) HU216831B (zh)
IL (1) IL104821A (zh)
MX (1) MX9300948A (zh)
NO (1) NO943101D0 (zh)
NZ (1) NZ249346A (zh)
TW (1) TW226374B (zh)
WO (1) WO1993017019A1 (zh)
ZA (1) ZA931146B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (en) 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080727T3 (es) * 1988-02-23 1996-02-16 Merrell Pharma Inc Uso de quinolizina y derivados de quinolizinona en la fabricacion de medicamentos.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
ZA931146B (en) 1993-09-14
HU216831B (hu) 1999-09-28
HUT68249A (en) 1995-06-28
IL104821A (en) 1997-01-10
NO943101L (no) 1994-08-23
KR950700297A (ko) 1995-01-16
CA2130563A1 (en) 1993-09-02
EP0628043A1 (en) 1994-12-14
FI943872A (fi) 1994-08-23
FI943872A0 (fi) 1994-08-23
IL104821A0 (en) 1993-06-10
WO1993017019A1 (en) 1993-09-02
MX9300948A (es) 1993-08-01
HU9402436D0 (en) 1994-10-28
NZ249346A (en) 1995-10-26
AU675060B2 (en) 1997-01-23
KR100287933B1 (ko) 2001-05-02
FI105917B (fi) 2000-10-31
NO943101D0 (no) 1994-08-23
AU3603493A (en) 1993-09-13
JPH07504192A (ja) 1995-05-11
CA2130563C (en) 1997-11-11

Similar Documents

Publication Publication Date Title
DK0634000T3 (zh)
DK0652790T3 (zh)
DK0553875T3 (zh)
DK0551248T3 (zh)
DK0603481T3 (zh)
DK0632741T3 (zh)
DK0576346T3 (zh)
DK0571874T3 (zh)
DK148492D0 (zh)
DK0564197T3 (zh)
DK0574276T3 (zh)
DK0596569T3 (zh)
DK0581726T3 (zh)
DK0597323T3 (zh)
DK0559942T3 (zh)
AU631518B2 (zh)
DK146492D0 (zh)
BRPI9204323A2 (zh)
AU2098792A (zh)
DK11192D0 (zh)
DK127492D0 (zh)
ECSDI920062S (zh)
AU1849392A (zh)
AU2054092A (zh)
AU639201B1 (zh)

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent